What Lies Ahead -
Innovations in IBD Grants Researcher
Institution
Dr. Charles Bernstein
University of Manitoba
Co-investigators: Dr. Laura Targownik University of Manitoba Dr. Hillary Steinhart Mount Sinai Hospital Dr. John Marshall McMaster University
Dr. Stephen Girardin
University of Toronto
Co-investigator: Dr. David Prescott University of Toronto
Dr. Andrew Stadnyk
IWK Health Centre
Co-investigator: Dr. Anthony Otley IWK Health Centre
Dr. Stuart Turvey University of British Columbia
Co-investigators: Dr. Laura Sly
Dr. Hong Yang
University of British Columbia
University of British Columbia
Development of anti-inflammatory nanomedicine for inflammatory bowel disease
$50,000 (1 year)
An innovative approach to cell therapy for Crohn’s disease
$50,000 (1 year)
Targeted genome editing in human intestinal epithelial cells
$50,000 (1 year)
Discovery Grants 2014-2017
In May 2014 our Grant Review Committee met to identify the most promising research to fund in the coming year and we are pleased to announce the additional nine Grant-in-Aid and four Innovations in IBD projects will be funded. These programs support high-quality innovative research projects that will enhance our understanding of Crohn’s disease and ulcerative colitis and have the potential to cure or more effectively control these diseases.
Project
Denosumab (common osteoporosis drug) for the treatment of Crohn’s disease
Investment
$50,000 (1 year)
RESEARCH REPORT 2014 | 22
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32